CD19 Antibody (CVID3/429), PE/Atto594, Novus Biologicals™

CD19

Monoclonal

PE/ATTO 594

PBS with 0.05% Sodium Azide

CD19

Recombinant full-length human CD19 protein (Uniprot: P15391)

0.1 mL

Primary

CD19 is a transmembrane glycoprotein that contains two extracellular immunoglobulin-like domains. CD19 is present in both benign and malignant B-cells and is considered to be the most reliable surface marker of this lineage over a wide range of maturational stages. In normal lymphoid tissue, CD19 is observed in germinal centers, in mantle zone cells, and in scattered cells of the inter-follicular areas. Anti-CD19 exhibits an overall immunoreactivity pattern similar to those of the antibodies against CD20 and CD22. However, in contrast to CD20, expression of CD19 is continuous throughout B-cell development and through terminal differentiation of B-cells into plasma cells. Anti-CD19 positivity is seen in the vast majority of B-cell neoplasms commonly at a lower intensity than normal B-cell counterparts. Plasma cell neoplasms are nearly always negative, as are T-cell neoplasms

Store at 4°C in the dark. Do not freeze.

Flow Cytometry

CVID3/429

Flow Cytometry

B4, B-lymphocyte antigen CD19, B-lymphocyte surface antigen B4, CD19 antigen, CD19 molecule, CVID3, Differentiation antigen CD19, MGC12802, T-cell surface antigen Leu-12

Mouse

Protein A or G purified

Adaptive Immunity, B Cell Development and Differentiation Markers, Cytokine Research, Immunology, Innate Immunity, Mesenchymal Stem Cell Markers, Myeloid derived Suppressor Cell, Signal Transduction, Stem Cell Lines, Stem Cell Markers

930.0

Human, Monkey, Primate

IgG1 κ